Posted On: 01/30/2014 10:41:30 AM
Post# of 89448
$BIIB Up to date company activities and other important information about $BIIB
$BIIB
DD Notes ~ http://www.ddnotesmaker.com/BIIB
##### recent news/filings ~ source: finance.yahoo.com
Thu, 30 Jan 2014 14:54:27 GMT ~ 2:03 am Biogen Idec and UCB enter agreements to commercialize multiple sclerosis and hemophilia therapies in Asia
- 2:03 am Biogen Idec and UCB enter agreements to commercialize multiple sclerosis and hemophilia therapies in Asia
read full: http://finance.yahoo.com/news/inplay-briefing....html#biib
*********************************************************
Thu, 30 Jan 2014 12:38:21 GMT ~ Biogen price target raised to $377 from $293 at Brean Capital
- Biogen price target raised to $377 from $293 at Brean Capital
read full: http://www.theflyonthewall.com/permalinks/ent...an-Capital
*********************************************************
Thu, 30 Jan 2014 06:00:00 GMT ~ Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
- CAMBRIDGE, Mass. & BRUSSELS, Belgium--(BUSINESSWIRE)-- Biogen Idec (NASDAQ:BIIB - News) and UCB (Euronext:UCB) announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China. As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA®, FAMPYRA®, AVONEX®, TYSABRI®, PLEGRIDY™ and Daclizumab High-Yield Process (DAC HYP). The relationship also includes ELOCTATE™ and ALPROLIX™, Biogen Idec’s investigational long-acting recombinant candidates for hemophilia A and B, respectively. “Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible,” said Carlos Dourado, Senior Vice President, Emerging Markets at Biogen Idec.
read full: http://au.finance.yahoo.com/news/biogen-idec-...00363.html
*********************************************************
Thu, 30 Jan 2014 06:00:00 GMT ~ Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
- Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South
read full: http://finance.yahoo.com/news/biogen-idec-ucb...00843.html
*********************************************************
Wed, 29 Jan 2014 23:32:41 GMT ~ Novartis’ Fourth Quarter Earnings: 3 Key Takeaways
- Recent earnings report highlights key factors for future profitability.
read full: http://www.fool.com/investing/general/2014/01...lnk0000001
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=BIIB&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=BIIB&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BIIB/company-info
Ticker: $BIIB
OTC Market Place: Not Available
CIK code: 0000875045
Company name: Biogen Idec, Inc.
Company website: http://www.idecpharm.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/BIIB/filings
Latest financials: http://www.otcmarkets.com/stock/BIIB/financials
Latest news: http://www.otcmarkets.com/stock/BIIB/news - http://finance.yahoo.com/q/h?s=BIIB+Headlines
Major holdings: http://data.cnbc.com/quotes/BIIB/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=BIIB+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/BIIB.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=BIIB
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Biogen+Idec%2C+Inc...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...dec%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.idecpharm.com
Alexa: http://www.alexa.com/siteinfo/http://www.idecpharm.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.idecpharm.com
http://www.pennystocktweets.com/stocks/profile/BIIB
##### last known share structure ~ source: otcmarkets.com
Market Value: $70,268,622,416 a/o Jan 29, 2014
Shares Outstanding: 236,212,930 a/o Oct 21, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0005
##### business description ~ source: otcmarkets.com
IC
DD Notes ~ http://www.ddnotesmaker.com/BIIB
$BIIB
DD Notes ~ http://www.ddnotesmaker.com/BIIB
##### recent news/filings ~ source: finance.yahoo.com
Thu, 30 Jan 2014 14:54:27 GMT ~ 2:03 am Biogen Idec and UCB enter agreements to commercialize multiple sclerosis and hemophilia therapies in Asia
- 2:03 am Biogen Idec and UCB enter agreements to commercialize multiple sclerosis and hemophilia therapies in Asia
read full: http://finance.yahoo.com/news/inplay-briefing....html#biib
*********************************************************
Thu, 30 Jan 2014 12:38:21 GMT ~ Biogen price target raised to $377 from $293 at Brean Capital
- Biogen price target raised to $377 from $293 at Brean Capital
read full: http://www.theflyonthewall.com/permalinks/ent...an-Capital
*********************************************************
Thu, 30 Jan 2014 06:00:00 GMT ~ Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
- CAMBRIDGE, Mass. & BRUSSELS, Belgium--(BUSINESSWIRE)-- Biogen Idec (NASDAQ:BIIB - News) and UCB (Euronext:UCB) announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China. As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA®, FAMPYRA®, AVONEX®, TYSABRI®, PLEGRIDY™ and Daclizumab High-Yield Process (DAC HYP). The relationship also includes ELOCTATE™ and ALPROLIX™, Biogen Idec’s investigational long-acting recombinant candidates for hemophilia A and B, respectively. “Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible,” said Carlos Dourado, Senior Vice President, Emerging Markets at Biogen Idec.
read full: http://au.finance.yahoo.com/news/biogen-idec-...00363.html
*********************************************************
Thu, 30 Jan 2014 06:00:00 GMT ~ Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
- Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South
read full: http://finance.yahoo.com/news/biogen-idec-ucb...00843.html
*********************************************************
Wed, 29 Jan 2014 23:32:41 GMT ~ Novartis’ Fourth Quarter Earnings: 3 Key Takeaways
- Recent earnings report highlights key factors for future profitability.
read full: http://www.fool.com/investing/general/2014/01...lnk0000001
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=BIIB&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=BIIB&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BIIB/company-info
Ticker: $BIIB
OTC Market Place: Not Available
CIK code: 0000875045
Company name: Biogen Idec, Inc.
Company website: http://www.idecpharm.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/BIIB/filings
Latest financials: http://www.otcmarkets.com/stock/BIIB/financials
Latest news: http://www.otcmarkets.com/stock/BIIB/news - http://finance.yahoo.com/q/h?s=BIIB+Headlines
Major holdings: http://data.cnbc.com/quotes/BIIB/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=BIIB+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/BIIB.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=BIIB
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Biogen+Idec%2C+Inc...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...dec%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.idecpharm.com
Alexa: http://www.alexa.com/siteinfo/http://www.idecpharm.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.idecpharm.com
http://www.pennystocktweets.com/stocks/profile/BIIB
##### last known share structure ~ source: otcmarkets.com
Market Value: $70,268,622,416 a/o Jan 29, 2014
Shares Outstanding: 236,212,930 a/o Oct 21, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0005
##### business description ~ source: otcmarkets.com
IC
DD Notes ~ http://www.ddnotesmaker.com/BIIB
(0)
(0)
